An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma

Maria Lorenzi, Stella Arndorfer, Raquel Aguiar-Ibañez, Emilie Scherrer, Frank Xiaoqing Liu and Clemens Krepler

ABSTRACT

Objective: To determine the efficacy of pembrolizumab relative to other treatments used in stage III melanoma by conducting a systematic literature review (SLR) and network meta-analysis (NMA).

Methods: A SLR was conducted to identify randomized clinical trials (RCTs) evaluating approved adjuvant treatments including interferon-containing regimens, BRAF-inhibitors, and PD-L1 inhibitors in stage III melanoma patients. Relative treatment effects for recurrence-free survival (RFS) were synthesized using Bayesian NMA models that allowed for hazard ratios (HRs) to vary over time.

Results: Included studies formed a connected network of evidence composed of eight trials. In high-risk stage III patients, the HR for pembrolizumab vs observation decreased significantly over time with the superiority of pembrolizumab over observation becoming statistically meaningful before 3 months. By 9 months, the HR for pembrolizumab vs observation was statistically significantly lower than the HR for most other treatments vs observation, with the exception of ipilimumab and biochemotherapy due to overlapping 95% credible intervals. In BRAF+ patients, pembrolizumab was statistically significantly better than observation after 3 months. The HR for both BRAF-inhibitors vs observation increased significantly over time and pembrolizumab was statistically superior to both BRAF-inhibitors after 15 months.

Conclusions: Pembrolizumab results in statistically significantly improved RFS compared to all competing regimens after 9 months, except ipilimumab and biochemotherapy, for the adjuvant treatment of stage III melanoma. However, point estimate HRs vs observation for pembrolizumab are much lower than those for ipilimumab. In BRAF+ patients, the advantage of pembrolizumab versus competing interventions increases over time with respect to RFS.

Introduction

Malignant melanoma is one of the few remaining cancers that is increasing in incidence in developed countries worldwide. The rate of developing melanoma was 31.9 per 100,000 person years in men and 20.4 per 100,000 person years in women in the US in 2014. In 2015, the world regions with the greatest rates in both incidence and mortality were Australia, North America, Western Europe, Central Europe, and Eastern Europe. When diagnosed early, rates of survival are relatively high. However, Gershenwald and Scolyer state that the 5-year survival rates range from 93–69% for stage IIA–stage IIC melanoma compared to 99–97% for stage IA–IB and 94–87% for stage IIA–IIB melanoma. Similarly, 10-year survival rates decrease from 88% for stage IIA to 69% for stage IIC melanoma. Recurrence of stage III melanoma is moderate-to-high with 5-year recurrence-free survival ranging from 50–63% for stage IIA and 11–12% for stage IIB melanoma. Survival rates for stage III melanoma are significantly lower compared with those diagnosed with early stage melanoma, demonstrating a need for effective treatments in those diagnosed with high-risk melanoma. Until the results of the MSLT studies were released, complete lymphadenectomy with or without adjuvant therapy was the primary treatment for patients with stage III melanoma for patients with confirmed disease in the lymph nodes. Interferon-alpha (IFN-α) was the first treatment to provide meaningful improvement in relapse-free survival (RFS) and overall survival (OS) for these patients. A meta-analysis published in 2017 assessed clinical efficacy of IFN-α as adjuvant therapy and found that it significantly reduced the risk of relapse as well as improved overall survival regardless of dosage for patients with high-risk melanoma. In the several countries where adjuvant therapy for melanoma is routinely used, IFN-α was the only drug approved as adjuvant therapy for melanoma patients, until recently, when ipilimumab was approved in the US for adjuvant therapy.
In the past several years, clinical trials evaluating immune-checkpoint inhibitors, including PD-1 inhibitors and CTLA-4 inhibitors, for the adjuvant treatment of stage III melanoma have been published. EORTC 18071, conducted in high-risk stage III melanoma, demonstrated ipilimumab significantly improved RFS in this population compared to placebo (1-year rate of RFS = 63.5% [95% CI = 59.0–67.7%] vs 56.1% [51.5–60.5%]; hazard ratio (HR) for RFS = 0.75 [0.64–0.90]).

CheckMate 238, a phase III double-blind RCT in patients undergoing resection stage IIIb–IV melanoma, found that adjuvant therapy with nivolumab monotherapy offered significantly longer RFS compared to ipilimumab (1-year rate of RFS = 70.5% [95% CI = 66.1–74.5%] vs 60.8% [56.0–65.2%]; HR for RFS = 0.65 [0.53–0.81]). In a randomized, phase III double-blind trial, KEYNOTE 054, in patients with resected high-risk stage III melanoma, pembrolizumab monotherapy was associated with significantly longer recurrence-free survival (RFS) compared with placebo (1-year rate of RFS = 76.4% [95% CI = 71.3–78.9%] vs 61.0% [56.5–65.1%]; HR for RFS = 0.57 [0.43–0.74]).

In addition to immune-checkpoint inhibitors, BRAF/MEK inhibitors such as vemurafenib and dabrafenib + trametinib combination therapy have been evaluated for the treatment of stage III BRAF V600 mutated melanoma. COMBI-AD, a phase III double-blind study, assessed dabrafenib in combination with trametinib vs placebo for the adjuvant treatment of stage III melanoma in BRAF V600E/K-mutant melanoma. Dabrafenib in combination with trametinib in the COMBI-AD trial was associated with significantly lower risk of recurrence vs placebo (1-year rate of RFS = 88% [95% CI = 85–91%] vs 56% [51–61%]; HR for RFS = 0.49 [0.40–0.59]). Finally, vemurafenib vs placebo was evaluated in BRAF V600 mutation positive patients for the adjuvant treatment of stage III melanoma in a phase III, double-blind trial, BRIM-8 cohort 2. Findings from BRIM-8 cohort 2 showed that vemurafenib did not statistically significantly reduce risk of recurrence vs placebo (HR for RFS = 0.80 [95% CI = 0.54–1.18]) in stage III BRAF V600 mutation positive patients.

Given the relatively new development of these therapies and lack of evidence in comparative treatment efficacy of currently available adjuvant treatments for adult patients with high-risk stage III melanoma independent of BRAF-status as well as for the BRAF-mutated population, there is a need to formally assess relative treatment effects. In cases where a connected network of evidence is formed, network meta-analysis (NMA) provides a valid alternative for simultaneous comparison of all included interventions and estimates relative treatment effects between any pair of interventions in the network. The purpose of this study is to compare the relative efficacy, specifically RFS, given that this endpoint is available for all treatments of interest, of pembrolizumab to additional competing interventions for the adjuvant treatment of high-risk stage III melanoma patients, independent of BRAF-status, as well as for BRAF-mutated patients by means of network meta-analysis.

### Methods

#### Systematic literature review

A systematic literature review (SLR) was performed using OVID MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The final date for the literature searches was February 8, 2018. Pre-specified selection criteria regarding study population, interventions, comparators, outcomes, and study design (PICOS) are enumerated in Table 1. The PICOS captured RCTs that (1) were conducted in stage III melanoma patients, (2) evaluated recommended interventions based on the National Comprehensive Cancer Network (NCCN) guidelines, (3) reported outcomes of interest, and (4) were published in English. The Scottish Intercollegiate Guidelines Network (SIGN) filter for RCTs was used to limit study design. MeSH terms and keywords were used to identify studies by population, interventions, and comparators. In addition, 2016 and 2017 conference proceedings from the European Society of Medical Oncology (ESMO), The Society of Melanoma Research (SMR), Society for Immunotherapy of Cancer (SITC), American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO) were searched. A hand search of the US National Institutes of Health Clinical Trials Registry was also performed. Full search strategies are available in Supplementary Tables S1–S5.

Two reviewers independently screened titles and abstracts of articles and conference proceedings for potentially eligible studies. Full-text publications corresponding to included studies were then retrieved and screened in duplicate. A PRISMA flow diagram for the SLR is provided in Supplementary Figure S1. Discrepancies were resolved by discussion between the pair of reviewers. Once the list of included studies was finalized, trial characteristics, patient characteristics, and study results were extracted in duplicate from all eligible publications.

#### Table 1. Study selection criteria to identify trials for the SLR

| Criteria | Description |
|----------|-------------|
| Population | Stage III melanoma |
| Sub-groups of interest | • BRAF mutation status |
| Interventions | Pembrolizumab |
| | Interferon (IFN)-α2a |
| | IFN-α2b |
| | Pegylated IFN-α2b |
| | Nivolumab |
| | Ipilimumab |
| | Dabrafenib in combination with trametinib |
| | Temozolomide in combination with cisplatin |
| | Vemurafenib |
| Comparisons | Placebo or best supportive care (BSC) |
| | Any intervention of interest as monotherapy or in combination |
| | Any treatment that facilitates an indirect treatment comparison |
| Outcomes | Recurrence-free (or relapse-free) survival (RFS) |
| Study design | Randomized controlled trials |
| | Systematic literature reviews |
| | Meta-analyses |
| Other | English language |
| | No time restriction |
Study quality was assessed using Cochrane Collaboration’s Risk of Bias tool to evaluate six key domains: sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias.

**Network meta-analysis**

In the absence of head-to-head clinical trial data, NMA is a viable option to obtain relative treatment effects among interventions that have not been directly compared with each other. In order to synthesize multiple trials and data sources with minimal bias, NMA depends on careful consideration when defining prognostic factors and relative treatment effect modifiers. In NMA, only relative treatment effects from each trial are incorporated, thereby decreasing the risk that known and unknown prognostic factors will affect results. However, in order to decrease risk that potential relative treatment effect modifiers will bias NMA results, a thorough feasibility assessment is conducted on the evidence base. The feasibility assessment is conducted prior to the NMA and ensures that trials meeting PICOS selection criteria are reasonably similar with respect to: (1) whether RCT evidence for the interventions of interest form an evidence base for the target population and outcome of interest; and (2) assess that trial characteristics, interventions characteristics, and patient characteristics that may affect treatment effects of trials included in the evidence are reasonably distributed. Trial characteristics assessed include study phase, trial initiation and completion, eligibility criteria, and risk of bias. Patient characteristics of interest were those that may act as potential treatment effect modifiers, such as age, sex, disease stage, ECOG performance status, melanoma sub-type, PD-L1 expression, and BRAF mutation status. After assessing heterogeneity, and excluding trials that differ from the target population and overall evidence base, the evidence was synthesized by means of NMAs.

Traditional NMA results for time-to-event outcomes are based on HR estimates, which rely on the proportional hazards assumption. When the proportional hazards assumption is violated, such as if hazard functions of competing interventions cross or if the calculated time-varying parameter (d1) is statistically significant as determined by its associated credible interval (CrI), an NMA model allowing for time varying HRs is appropriate. Jansen and Ouwens et al. have presented methods for NMA of survival data using a multidimensional treatment effect as an alternative to the synthesis of the constant HRs. The hazard functions of the interventions in a trial are modeled using known parametric survival functions or fractional polynomials, and the difference in the parameters are considered the multidimensional treatment effect, which are synthesized (and indirectly compared) across studies. With this approach, the treatment effects are represented by multiple parameters rather than a single parameter. By including additional parameters for treatment effects, the proportional hazards assumption is relaxed and the time-varying HR NMA model can more closely fit reported data.

This analysis was done for RFS, as it was the endpoint reported for all treatments of interest, which formed a connected network. For RFS, the following survival distributions were considered using a multivariate NMA framework, as proposed by Jansen: Weibull, Gompertz, and second-order fractional polynomials including $p_1 = 0$ or 1 and $p_2 = 0$ or 1. Second-order fractional polynomial models are extensions to the Weibull and Gompertz model, and allow for arc- and bathtub-shaped functions, which follow parametric distributions such as log-normal or log-logistic. For each treatment arm of each study in the NMA, the reported Kaplan-Meier curves were digitized and divided into intervals over the follow-up period. Within each interval, survival proportions are used to calculate patients at risk at the beginning of each interval as well as the incident number of deaths or recurrences, as a way to calculate the hazard rate corresponding to the underlying event probability, which is standardized by months.

Time-varying HR NMA results were presented as estimates for HRs of each intervention relative to the reference treatment, observation, up until 24 months, the maximum follow-up of KEYNOTE 054. Point estimates of HRs every 3 months, beginning at 3 months, are provided in tables for each treatment compared to observation. The best-fitting model for each analysis is presented, as determined by the lowest deviance information criterion (DIC). Statistically significant variations over time were justified by calculating a 95% credible interval (CrI) around the time-varying parameter, $d_1$. Furthermore, if 95% CrIs of interventions vs observation no longer overlapped with each other, this determined statistical differentiation of treatments. All analyses were performed using R version 3.4.0 (R Project for Statistical Computing) with the package R2JAGS version 0.5.7 (OpenBUGS Project Management Group).

**Results**

**Systematic literature review**

Initial literature searches identified 4,857 references across all databases. After removal of duplicates, this number was reduced to 3,898 articles. After exclusion on the basis of titles and abstracts, 170 papers were retrieved for full-text review. Overall, a total of 18 full-text publications, three conference abstracts, one citation from the clinical trials registry, and one citation from an unpublished clinical study report met the inclusion criteria in full; these 23 included publications corresponded to 12 unique trials. The study identified through the clinical trials registry was BRIM-8 and the unpublished clinical study report was KEYNOTE 054, both of these trials were published after the date of the systematic database search. The included trials and their corresponding publications are listed in Table 2.

**Feasibility assessment**

**Outcomes of interest**

Relapse (or recurrence)-free survival (RFS) was reported in 11 trials identified in the SLR. Caraceni et al. did not report
RFS as an outcome. RFS was defined in six trials: BRIM-8, CheckMate 238, COMBI-AD, KEYNOTE 054, Lian 2013, and the Nordic IFN trial. The remaining five trials that reported RFS did not define how RFS was measured. Of the six trials defining RFS, five trials defined RFS as the time from randomization until date of the first recurrence (local, regional, or distant metastasis), death, or end of follow-up. Nordic IFN trial defined RFS as the time until first verified relapse or death, or end of follow-up.

### Trial characteristics

Trial characteristics of included RCTs were reasonably similar (Table 2). Primary completion dates ranged from 2003–2018. Out of the 12 trials included from the SLR, five were double-blind, five were open-label, and two did not report masking status of the trial (Caraceni et al. and Lian et al.). According to the Cochrane Collaboration’s tool, most trials had low risk of bias, as shown in Supplementary Tables S6 and S7. Eligibility criteria for most trials included patients with ECOG performance scores of 0 or 1. Caraceni et al. measured performance score based on the Karnofsky scale, specifically enrolling patients with Karnofsky 100, which is the equivalent of ECOG 0. Additionally, two trials did not report ECOG performance score eligibility criteria (EORTC 18952 and WHO MPT 16). Of trials reporting proportions of stage II and stage IV patients, all reported stage III sub-group data.

### Intervention characteristics

The trials included in the feasibility assessment included the following interventions: BRAF-inhibitors (vemurafenib and dabrafenib + trametinib), interferon-containing regimens (IFN-α2a, IFN-α2b, pegylated IFN-α2b, and biochemotherapy), ipilimumab, nivolumab, pembrolizumab, and observation or placebo. Although biochemotherapy was not listed in the SLR search strategy, it was a combination of cisplatin + vinblastine + dacarbazine + interleukin-2 (IL-2) + IFNα + filgrastim (G-CSF), which included an intervention of interest, IFN. Intervention characteristics of included trials, including dosage and frequency and planned duration of treatment, were reasonably similar across trials. Treatments were administered via IV for five trials (nivolumab, ipilimumab, IFN-α2b, cisplatin, and biochemotherapy), oral tablets for four trials (temozolomide, vemurafenib, dabrafenib, and trametinib), and subcutaneously for eight trials (IFN-α2a, IFN-α2b, biochemotherapy, and pegylated IFN-α2b). Ipilimumab was administered in two trials, CheckMate 238 and EORTC 18071, at a dosage of 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks for 1 year (CheckMate 238) or 3 years (EORTC 18071), or until disease recurrence, unacceptable toxicity, major protocol violation, or treatment refusal. However, although initial ipilimumab treatment was similar in CheckMate 238 and EORTC 18071, maintenance treatment differed between the two trials. Specifically, in CheckMate 238, ipilimumab was administered every 12 weeks for up to 1 year, compared to EORTC 18071, which administered ipilimumab every 12 weeks for 3 years. Although initial treatment of ipilimumab was the same for both CheckMate 238 and EORTC 18071, the duration of the ipilimumab maintenance period greatly differed. Maintenance treatment for ipilimumab began at week 24 for both CheckMate 238 and EORTC 18071, however, maintenance treatment was up to 1 year for CheckMate 238 and to 3 years for EORTC 18071.
Differences in maintenance therapy duration, for the ipilimumab arms in CheckMate 238 and EORTC 18071, may lead to differences in treatment efficacy; therefore, the two ipilimumab arms cannot be considered equivalent.\(^5\) No background or concomitant therapies were reported by any trials included in the feasibility assessment. Crossover was not permitted in six trials; the remaining trials did not explicitly report whether they allowed crossover. Although KEYNOTE 054 allowed crossover in part 2 of the trial, this analysis reflects follow-up from part 1 of the trial, which did not allow crossover.

**Patient characteristics**

Differences identified in the ITT populations with respect to age, sex, ECOG status, BRAF status, and disease stage status are summarized in Table 3. Differences with respect to potential effect modifiers, such as BRAF status, disease stage, and melanoma sub-type were identified.

Ranging from 46–59 years, median age at baseline varied little between treatment arms. Similarly, sex distribution across trials had little variation, with all trials being majority male, except COMBI-AD and Lian, which consisted of 45% and 40% males, respectively.\(^26,38\) In trials reporting ECOG performance status (PS), the proportion of patients with PS of 0 or 1 ranged from 98% to 100%. Two trials reported small proportions of unknown or missing ECOG status, WHO MPT 16 and COMBI-AD.\(^39,42\) Few trials reported patients with stage II (n = 2 trials), stage IIIB (n = 1 trial), and stage IIIC (n = 1 trial) disease. Nordic IFN trial reported a small proportion of stage II patients (19%).\(^39\) EORTC 18952 included 26% stage IIIB patients, and BRIM-8 cohort 1 included 9% stage IIIC patients.\(^1,2,26\) Among the four trials reporting stage II, IIIB, and IIIC patients, three trials were composed of less than 25% stage II patients, and all four trials provided stage III sub-group data. Stage IIIA, IIIB, and IIIC proportions were reported in six trials, and stage III proportions were reported in five trials. Stage III patients, including sub-stages stage IIIA–IIIC, ranged from 74–100%. However, Lian \( et \ al \)\(^39\) reported only 29% of patients enrolled were stage III. Three trials did not report disease stage proportions: Caraceni, SWOG S0008, and WHO MPT 16.\(^24,41,42\) Only one trial, CheckMate 238, reported a population with stage IV patients, which was composed of 19% stage IV patients.\(^10\) Of note, although both SWOG S0008 and WHO MPT 16 did not report disease stage proportions, they both noted they only enrolled stage III patients.\(^10,41,42\) BRAF mutation status was reported in four trials: BRIM-8, CheckMate 238, COMBI-AD, and KEYNOTE 054. Both BRIM-8 and COMBI-AD were conducted in BRAF+ patients only, whereas 42–43% of patients enrolled in CheckMate 238 and KEYNOTE 054 were BRAF+.\(^10,11,14,26\) Two trials allowed mucosal melanoma patients, Lian (100%) and CheckMate 238 (3%), compared to the remaining trials which only enrolled patients with cutaneous melanoma.\(^10,38\) Furthermore, CheckMate 238 enrolled patients with acral and other rare sub-types of melanoma.\(^10\)

**Feasibility assessment summary**

Overall, the studies were determined to be of good quality and with minimal heterogeneity, although key differences

| Table 3. List of publications and key patient characteristics, arranged by trial. |
| --- |
| **Trial ID** | **Treatment** | **n** | **Median age (range)** | **Male (%)** | **ECOG 0 or 1 (%)** | **Stage IIIA (%)** | **Stage IIIB (%)** | **Stage IIIC (%)** | **Stage III (%)** |
| BRIM-8 cohort 1 | Vemurafenib | 157 | 51.0 (43.0–60.0)** | 84 (54%) | 155 (100%) | 36 (23%) | 106 (68%) | — | — |
| | Placebo | 157 | 49.0 (40.0–59.0)** | 88 (56%) | 157 (100%) | 39 (25%) | 106 (68%) | — | — |
| BRIM-8 cohort 2 | Vemurafenib | 93 | 53.0 (40.0–61.0)** | 52 (56%) | 92 (100%) | — | — | 93 (100%) | — |
| | Placebo | 91 | 50.0 (38.0–58.0)** | 59 (65%) | 91 (100%) | — | — | 91 (100%) | — |
| Caraceni 1998 | IFN-α2a | 37 | 46.0 (39.0–53.0)** | 22 (60%) | — | — | — | — | — |
| | Control | 30 | 49.5 (41.0–58.0)** | 20 (67%) | — | — | — | — | — |
| CheckMate 238 | Nivolumab | 453 | 56.0 (19.0–83.0) | 258 (57%) | — | — | 163 (36%) | 204 (45%) | — |
| | Ipilimumab (1 year) | 453 | 54.0 (18.0–86.0) | 269 (59%) | — | — | 148 (33%) | 218 (48%) | — |
| COMBI-AD | Dabrafenib + trametinib | 438 | 50.0 (18.0–89.0) | 195 (45%) | — | 132 (30%) | 169 (39%) | 181 (41%) | — |
| | Placebo | 432 | 51.0 (20.0–85.0) | 193 (45%) | — | 136 (31%) | 187 (44%) | 166 (38%) | — |
| EORTC 18071 | Ipilimumab (3 years) | 475 | 50.7* (20.0–84.0) | 296 (62%) | 474 (99%) | 98 (21%) | 213 (45%) | 164 (34%) | 475 (100%) |
| | Placebo | 476 | 51.5* (18.0–78.0) | 293 (62%) | 476 (100%) | 88 (18%) | 207 (44%) | 181 (38%) | 476 (100%) |
| EORTC 18952 | IFN-α2b (13 months) | 553 | 49.0 (17.0–74.0) | 312 (56%) | — | 412 (74%) | — | — | — |
| | IFN-α2b (25 months) | 556 | 50.0 (16.0–75.0) | 308 (55%) | — | 414 (74%) | — | — | — |
| | Observation | 279 | 47.0 (20.0–75.0) | 152 (54%) | — | 206 (74%) | — | — | — |
| EORTC 18991 | Pegylated IFN-α2b | 627 | 50.0 (19.0–70.0) | 366 (58%) | 627 (100%) | — | — | 627 (100%) | — |
| | Observation | 629 | 50.0 (18.0–70.0) | 367 (59%) | 629 (100%) | — | — | 629 (100%) | — |
| KEYNOTE 054 | Pembrolizumab | 514 | 54.0 (19.0–88.0) | 324 (63%) | 514 (100%) | 80 (16%) | 237 (46%) | 197 (38%) | 514 (100%) |
| | Placebo | 505 | 54.0 (19.0–83.0) | 304 (60%) | 505 (100%) | 80 (16%) | 230 (46%) | 195 (39%) | 505 (100%) |
| Lian 2013 | Observation | 63 | 57.0 (25.0–80.0) | 28 (44%) | — | — | — | 21 (33%) | — |
| | High-dose IFN-α2b | 63 | 55.0 (26.0–84.0) | 25 (40%) | — | — | — | 16 (25%) | — |
| Nordic IFN trial | Temozolomide + cisplatin | 63 | 59.0 (18.0–75.0) | 23 (37%) | — | — | — | 19 (30%) | — |
| | Observation | 284 | 51.0 (18.0–76.0) | 167 (59%) | 284 (100%) | — | — | 229 (81%) | — |
| SWOG 50008 | IFN-α2b (12 months) | 285 | 53.0 (18.0–73.0) | 177 (62%) | 285 (100%) | — | — | 227 (80%) | — |
| | IFN-α2b (24 months) | 286 | 51.0 (22.0–77.0) | 183 (64%) | 286 (100%) | — | — | 233 (82%) | — |
| WHO MPT 16 | IFN-α2a | 225 | — | 131 (58%) | 222 (99%) | — | — | — | — |
| | Surgery + observation | 219 | — | 114 (52%) | 212 (97%) | — | — | — | — |

*Mean age used in trials where median age is not reported.
**IQR minimum and IQR maximum used in trials where age range is not reported.
†Biochemotherapy is a combination of cisplatin + vinblastine + dacarbazine + interleukin-2 (IL-2) + IFN-α + filgrastim (G-CSF).
were identified with respect to eligibility criteria, including melanoma sub-type and BRAF mutation status, intervention characteristics, and disease stage. Four trials were removed after the feasibility assessment, to ensure a homogenous evidence base: Caraceni 1998, CheckMate 238, Lian 2013, and EORTC 18952. Caraceni 1998 did not report any outcomes of interest, and therefore could not be included in the NMA. Lian 2013 was conducted exclusively in mucosal melanoma patients. Additionally, CheckMate 238 was largely conducted in a cutaneous melanoma patient population (85%), however, it did include small proportions of patients with acral, mucosal, and other melanoma sub-types. The rest of the evidence base was conducted in cutaneous melanoma patients. EORTC 18952 was conducted in stage IIB–IIIC patients and did not provide a stage III sub-group KM curve. The target population was stage III melanoma patients only. Therefore, trials conducted in stage III patients or that reported stage III sub-group analysis results were used in the NMA to ensure a homogenous evidence base.

Although CheckMate 238 provided sub-group data, reasons associated with both population and trial characteristics contributed to its exclusion from the evidence base. Specifically, CheckMate 238 was excluded due to differences in intervention administration of ipilimumab compared to EORTC 18071, which also administered ipilimumab, and patient population compared to the remaining trials in the evidence base. Differences in both patient population and intervention administration are described in the NICE appraisal consultation document for nivolumab in adjuvant treatment of resected stage III and IV melanoma. CheckMate 238 compared nivolumab to ipilimumab, rather than observation, and therefore was connected to the network by EORTC 18071, which compared ipilimumab to observation. Ipilimumab was administered every 3 months for up to 1 year or until disease progression in CheckMate 238, whereas, ipilimumab was administered every 3 months for up to 3 years or until disease progression, an unacceptable level of toxic effects, major protocol violation, or withdrawal of consent in EORTC 18071. Furthermore, CheckMate 238 only included stage IIIB, IIIC, and resected stage IV patients, whereas EORTC 18071 enrolled stage IIA-IIIIC patients, but did not enroll stage IV patients. Differences with respect to ipilimumab treatment duration and patient populations with respect to disease stage and melanoma sub-type in CheckMate 238 could not be adjusted, which would lead to biased estimates of nivolumab vs competing interventions, therefore, it was excluded from NMAs. Connected networks of evidence were constructed for RFS after completion of the feasibility assessment in stage III melanoma patients consisting of six trials (Figure 1) as well as for RFS in BRAF + patients consisting of three trials (Figure 2), respectively.

A sub-group analysis for RFS was conducted in BRAF + patients only, as BRAF mutation status is a known treatment effect modifier. Of note, BRAF inhibitors were

* Denotes comparator is “Placebo”, assumed to be equivalent to “Observation”
† Denotes hazard ratio was estimated from Kaplan-Meier curve

Figure 1. Network of evidence for recurrence-free survival, Stage III.
not included in the RFS stage III NMA, as these treatments are not considered relevant comparators for efficacy outcomes in a BRAF-unselected population.

Network meta-analysis

Networks of evidence were constructed for RFS in stage III and in BRAF+ melanoma patients, as seen in Figures 1 and 2. The best-fitting second order fractional polynomial (FP) model as determined by the lowest DIC for each network of evidence as well as HRs by time-point are presented for stage III RFS (Figure 3(a) and Table 4) and the sub-group analysis for RFS in BRAF+ patients (Figure 3(b) and Table 5). Time-varying HR NMAs are presented below, as the proportional hazards over time assumption was violated.

For RFS in stage III melanoma patients, the HR for pembrolizumab vs observation decreased significantly over time. The superiority of pembrolizumab vs observation became statistically meaningful by 3 months. The HRs for biochemotherapy and IFN-α2b (12 months) vs observation increased significantly over time based on the constructed 95% CrI for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero. After 9 months of follow-up, pembrolizumab vs observation was statistically differentiated from all regimens in the network except biochemotherapy and ipilimumab as evidenced by no longer overlapping 95% CrIs for the d1 estimate, which does not cross zero.

In BRAF+ patients, HR point estimates for pembrolizumab were statistically superior to observation for the follow-up months shown in Table 5. Based on the constructed 95% CrI for the d1 estimate, which does not cross zero, HRs for pembrolizumab vs observation did not statistically vary over time in BRAF+ patients. Therefore, pembrolizumab vs observation does not violate the proportional hazards assumption. Despite results for pembrolizumab over time, the increase in HRs of both BRAF-inhibitors vs observation over time was statistically important as confirmed by their associated d1 estimates and corresponding 95% CrIs. Because the HRs of both BRAF inhibitors increased significantly across all follow-up time, there was a statistical advantage for pembrolizumab vs the BRAF inhibitors after 15 months, as determined by no longer overlapping 95% CrIs between pembrolizumab and BRAF inhibitors vs observation (Figure 3(b)). Additionally, Table 5 provides supporting evidence that pembrolizumab offers improved RFS compared to both BRAF inhibitors. Specifically, HRs at time-points after 12 months show that pembrolizumab offers statistically significantly better RFS than observation, whereas both BRAF-inhibitors do not. By 24 months, both BRAF inhibitors are statistically inferior to observation, as evidenced by HRs and 95% CrIs vs observation in Table 5.

Discussion

The SLR identified 12 studies that met PICOS criteria, and were then assessed for heterogeneity in the feasibility assessment. Differences with respect to disease stage and trial characteristics led to the removal of four trials, thus eight trials were included in the final evidence base. Of these eight trials, six were included in the stage III analysis and three were included in the BRAF+ sub-group analysis. Findings in the stage III analysis suggest that pembrolizumab had statistically better RFS compared to all interventions after 9 months, with the exception of biochemotherapy and ipilimumab. Throughout time, pembrolizumab was not statistically differentiated from biochemotherapy and ipilimumab, although pembrolizumab did produce numerically better HRs after 6 months compared with both biochemotherapy and ipilimumab. However, comparisons made with biochemotherapy must be made with caution as relative treatment effect
Figure 3. Results of fixed-effects time-varying hazards network meta-analyses for recurrence-free survival (a) in Stage III melanoma patients with treatment effects as hazard ratio over time relative to observation under the best-fitting second order fractional polynomial model, (p1 = 0, p2 = 0) and (b) in BRAF+ melanoma patients with treatment effects as hazard ratio over time relative to observation under the best-fitting 2nd order fractional polynomial model (p1 = 0, p2 = 0).

Table 4. Time-varying hazard ratios of recurrence-free survival at select follow-up times for competing interventions vs observation, Stage III.

| Months | Pembrolizumab | Ipilimumab | Biochemotherapy | Interferon-α2a | Interferon-α2b (12 months) | Interferon-α2b (24 months) | Pegylated Interferon-α2b |
|--------|---------------|------------|-----------------|-----------------|----------------------------|---------------------------|--------------------------|
| 3      | 0.62 (0.50–0.77)* | 0.80 (0.64–1.00) | 0.34 (0.18–0.65)* | 0.74 (0.51–1.07) | 0.46 (0.29–0.71)* | 0.75 (0.51–1.13) | 0.80 (0.65–1.00) |
| 6      | 0.51 (0.41–0.65)* | 0.76 (0.63–0.91)* | 0.47 (0.30–0.73)* | 0.85 (0.66–1.10) | 0.61 (0.45–0.84)* | 0.78 (0.59–1.03) | 0.83 (0.71–0.98)* |
| 9      | 0.46 (0.35–0.61)* | 0.74 (0.61–0.89)* | 0.56 (0.38–0.82)* | 0.93 (0.73–1.17) | 0.73 (0.56–0.96)* | 0.79 (0.61–1.03) | 0.85 (0.74–0.98)* |
| 12     | 0.43 (0.32–0.58)* | 0.72 (0.58–0.89)* | 0.64 (0.44–0.92)* | 0.98 (0.76–1.26) | 0.83 (0.64–1.08) | 0.80 (0.61–1.05) | 0.87 (0.75–1.00) |
| 15     | 0.60 (0.29–0.57)* | 0.71 (0.56–0.90)* | 0.70 (0.48–1.03) | 1.03 (0.78–1.34) | 0.91 (0.70–1.20) | 0.81 (0.60–1.09) | 0.88 (0.75–1.02) |
| 18     | 0.39 (0.27–0.56)* | 0.70 (0.54–0.91)* | 0.76 (0.51–1.14) | 1.06 (0.79–1.43) | 0.99 (0.74–1.32) | 0.82 (0.59–1.13) | 0.88 (0.75–1.04) |
| 21     | 0.37 (0.25–0.55)* | 0.69 (0.52–0.92)* | 0.81 (0.53–1.26) | 1.10 (0.80–1.51) | 1.05 (0.78–1.44) | 0.82 (0.58–1.17) | 0.89 (0.75–1.06) |
| 24     | 0.36 (0.23–0.54)* | 0.69 (0.51–0.93)* | 0.86 (0.55–1.38) | 1.13 (0.80–1.59) | 1.12 (0.81–1.56) | 0.83 (0.57–1.20) | 0.90 (0.75–1.08) |

*Statistically significant results.
were largely similar in trial and patient characteristics. As outlined in the PICOS, stage III melanoma was of interest; however, some trials reported disease stages other than stage III. Therefore, in cases where stage II or stage IV patients were included, only stage III sub-group data was used to ensure a homogenous evidence base.

Notably, four trials differed with respect to eligibility criteria, disease stage, and treatment duration. These four trials were removed from the NMA as described in the feasibility assessment to ensure a close match between the analysis population and population of interest in differences that may modify relative treatment effects. Furthermore, because BRAF mutation status is a known treatment effect modifier for BRAF-targeted drugs, a sub-group analysis was conducted in this population to assess relative treatment effects in BRAF+ patients only. All analyses were conducted using a time-varying HR model rather than a proportional hazards model, due to violations of the proportional hazards assumption in both the stage III and BRAF+ sub-group analyses. Treatments that did not violate the proportional hazards in the stage III analyses were: ipilimumab, IFN-α2a, IFN-α2b (24 months), and pegylated IFN-α2b. Furthermore, pembrolizumab did not violate the proportional hazards assumption in the BRAF+ sub-group analyses. However, given the observed statistically significant changes over time for a number of treatments in both the stage III and BRAF+ NMA results, the proportional hazards assumption is violated. Consequently, the use of time-varying HR models are more appropriate.

Given the limited number of trials included in all analyses, there was insufficient data to reliably estimate between-study heterogeneity. Consequently, results are based on a fixed-effects model, despite a preference for a random-effects model, because of its assumption that between-study differences in treatment effect can arise from between-study heterogeneity. Because the fixed-effects model used implies that differences in treatment effects between studies can only arise from sampling differences, some credible intervals may be unrealistically narrow and should be interpreted with caution. Moreover, comparisons for pembrolizumab to all competing interventions were based on single trials. Given the structure of the network, comparisons to biochemotherapy were mediated by multiple treatment comparisons, and were, therefore, more uncertain. Additionally, sub-group data was not available for BRAF status by disease stage for BRIM-8, thus the all-comer population was used for the BRAF+ sub-group analysis which may impact relative treatment effects. Finally, as stated in the feasibility assessment, CheckMate 238 was removed based on trial and patient characteristic differences. However, the removal of CheckMate 238 no longer allowed relative treatment effects to be assessed in all available treatments for the adjuvant treatment in stage III melanoma. Heterogeneity adjustments were not possible, therefore, this NMA does not represent a complete narrative with respect to all available treatments for adjuvant stage III melanoma.

Despite some limitations to this analysis, there are some recognizable strengths in our analysis. Guided by pre-defined eligibility criteria outlined by the PICOS, the SLR process

| Months | Pembrolizumab HR vs observation (95% CrI) | Dabrafenib + trametinib HR vs observation (95% CrI) | Vemurafenib HR vs observation (95% CrI) |
|--------|------------------------------------------|-----------------------------------------------|---------------------------------|
| 3      | 0.60 (0.41–0.89)*                        | 0.09 (0.06–0.15)*                             | 0.19 (0.08–0.40)*               |
| 6      | 0.48 (0.34–0.66)*                        | 0.24 (0.17–0.32)*                             | 0.48 (0.28–0.79)*               |
| 9      | 0.42 (0.28–0.63)*                        | 0.41 (0.32–0.52)*                             | 0.83 (0.53–1.31)                |
| 12     | 0.38 (0.23–0.63)*                        | 0.60 (0.48–0.76)*                             | 1.23 (0.78–2.00)                |
| 15     | 0.35 (0.19–0.63)*                        | 0.82 (0.64–1.04)                              | 1.66 (1.02–2.90)*               |
| 18     | 0.33 (0.17–0.64)*                        | 0.80 (0.63–1.07)                              | 2.13 (1.23–3.40)*               |
| 21     | 0.32 (0.15–0.65)*                        | 1.28 (0.96–1.74)                              | 2.63 (1.43–5.28)*               |
| 24     | 0.30 (0.14–0.65)*                        | 1.54 (1.11–2.16)*                             | 3.16 (1.62–6.77)*               |

*Statistically significant results.
involved highly sensitive searches of peer-reviewed literature, as well as searches of recent conferences and clinical trial registrations to identity any unpublished completed trials with results available. Although fixed-effects were used due to lack of trial data to generate a stable heterogeneity parameter, the thorough feasibility assessment acted as a way to decrease heterogeneity by removing trials that contained factors which would likely bias relative treatment effects. Traditional NMA reports pairwise HRs, which assumes that treatment effects do not vary over time. Although traditional NMAs were carried out, violations of the proportional hazards were observed for several treatments insinuating that pairwise HR results are not appropriate. The use of time-varying HR NMA rather than traditional NMA allowed for treatments to vary over time according to various fractional polynomial models. This is especially important for treatments that violated the proportional hazards assumption, such as the BRAF-inhibitors, which are known to rapidly lose efficacy after 6 months. With the time-varying HR approach, relative treatment effects are represented by multiple parameters rather than a single parameter, thus allowing more flexibility necessary to accurately depict treatment efficacy over time.

Conclusions

Standard treatment for patients with primary melanoma with or without regional metastases to lymph nodes is surgery followed by adjuvant therapy, but lack of direct evidence comparing standard of care treatment options with newer treatment options, such as immunotherapy, prevents adequate assessment of relative treatment efficacy in patients with higher-risk of recurrent melanoma. This analysis shows RFS benefit provided by pembrolizumab monotherapy over standard of care agents for the adjuvant treatment of stage III melanoma, overall, and for BRAF+, with the benefit over competing interventions increasing over time.

Transparency

Declaration of funding

Funding for this study and development of the manuscript was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ.

Declaration of financial/other relationships

ML and SA are employees of Precision Xtract, a healthcare consultancy contracted by Merck & Co., Inc. to conduct evidence synthesis projects. RAI, CK, ES, and FXL are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. JDA peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References

[1] Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–548.

[2] Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2014. Bethesda, MD: National Cancer Institute; 2017.

[3] Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177:134–140.

[4] Gershenson JD, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018;25:2105–2110.

[5] Rutkowskis P, Ługowska I. Follow-up in melanoma patients. Mem. 2014;7:83–86.

[6] Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–2222.

[7] Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. JCO. 1996;14:7–17.

[8] Ives NJ, Suciuc S, Eggermont AMM, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer. 2017;82:171–183.

[9] Eggermont Amc-S V, Grob JJ, Dummer R, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. [Erratum appears in Lancet Oncol. 2015 Jun;16(6):e262; PMID: 26065611] [Clinical Trial, Phase III;Randomized Controlled Trial;Research Support, Non-U.S. Gov’t]. Lancet Oncol. 2015;16(5):522–530.

[10] Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma [Clinical Trial, Phase III;Comparative Study;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov’t]. N Engl J Med. 2017;377:1824–1835.

[11] Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–1801.

[12] Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage iii melanoma. JCO. 2018;36;JCO1801219–JCO1801219.

[13] Lewis K, Maio M, Mandala M, et al. BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419) [Journal: Conference Abstract]. JCO. 2014;32(15 SUPPL. 1):TPS9118–TPS9118. Conference start: 2014 May 30 Conference End: 2014 Jun 3. English.

[14] Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018;19:510–520.

[15] Ades AE. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Statist Med. 2003;22:2995–3016.

[16] Caldwell DM, Ades AE, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900.

[17] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statist Med. 2004;23:3105–3124.

[18] Network NCC. Melanoma (Version 1. 2018). 2018 [updated 2017 Dec 18; cited Feb 2018]: Available from: https://www.nccn.org/patients/guidelines/melanoma/files/assets/common/downloads/files/melanoma.pdf

[19] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

[20] Cope S, Zhang J, Saleten S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12:1–17.
[21] Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.

[22] Ouwens M, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Method. 2010;1:258–271.

[23] Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012;12:152–152.

[24] Caraceni A, Gangeri L, Martini C, et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial [Clinical Trial;Randomized Controlled Trial]. Cancer. 1998;83:482–489.

[25] Weber J, Mandala M, Del Vecchio M, et al. LBA8_PR Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238). Ann Oncol. 2017;28:v605–v649.

[26] Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma [Clinical Trial, Phase III;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. N Engl J Med. 2017;377:1813–1823.

[27] Hauschild A, Santinami M, Long GV, et al. LBA6_PRCOMBI-AD: adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma. Ann Oncol. 2017;28:v631.

[28] Coens C, Suciu S, Chiarion-Sileni V, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol. 2017;18:393–403.

[29] Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845–1855.

[30] Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. Ann Oncol. 2016;27:LBA2 PR.

[31] Eggermont Ams S, MacKie R, Ruka W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIB/III melanoma (EORTC 18952): randomised controlled trial [Clinical Trial;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.]. Lancet. 2005;366:1189–1196.

[32] Eggermont Ams S, Rutkowski P, Kruit WH, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB/III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity [Comparative Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. Eur J Cancer. 2016;55:111–121.

[33] Eggermont Ams S, Santinami M, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial [Clinical Trial, Phase III;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. Lancet. 2008;372:117–126.

[34] Fusí Ac S, Busse A, Suciu S, et al. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) [Clinical Trial, Phase III;Multicenter Study;Randomized Controlled Trial;Research Support, N.I.H., Extramural;Research Support, Non-U.S. Gov't]. Eur J Cancer. 2009;45:3189–3197.

[35] Bottomley AC S, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. [Erratum appears in J Clin Oncol. 2009 Sep 20;27(27):4630 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected] [Clinical Trial, Phase III;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. J Clin Oncol. 2009;27:2916–2923.

[36] Eggermont Ams S, Testori A, Santinami M, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma [Clinical Trial, Phase III;Multicenter Study;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. JCO. 2012;30:3810–3818.

[37] Herndon TM, Demko SG, Jiang X, et al. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma [Multicenter Study; Randomized Controlled Trial]. Oncologist. 2012;17:1323–1328.

[38] Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma [Clinical Trial, Phase II;Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. Clin Cancer Res. 2013;19:4488–4498.

[39] Hansson Ja S, Bastholt L, Brandberg Y, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial [Clinical Trial, Clinical Trial, Phase III;Randomized Controlled Trial;Research Support, Non-U.S. Gov't; Research Support, Non-U.S. Gov't]. Lancet Oncol. 2011;12:144–152.

[40] Wihinen P, Tervahartiala T, Sorsa T, et al. Benefit of adjuvant interferon alfa-2b (IFN-alpha) therapy in melanoma patients with high serum MMP-8 levels [Randomized Controlled Trial;Research Support, Non-U.S. Gov't]. Cancer Immuno Immunother. 2015;64:173–180.

[41] Fialherty LE, Othus M, Atkins MB, et al. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma—an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014;32:3771–3778.

[42] Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial [Clinical Trial;Multicenter Study;Randomized Controlled Trial]. Lancet. 2001;358:866–869.

[43] Oken MM, Creech RH, Torrey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–656.

[44] Cascinelli N, Santinami M, Maurichi A, et al. World Health Organization experience in the treatment of melanoma. Surg Clin North Am. 2003;83:405–416.

[45] NICE. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. In: Consultation A, editor. nice.org.uk: NICE; 2018.

[46] Bhatia P, Friedlander P, Zakaria EA, et al. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med. 2015;3:24–24.

[47] Kabirraaj Toor MRM, Jansen JP, Gooden K, et al. Comparative efficacy and safety of nivolumab versus other treatment for resected melanoma in adults: a systematic literature review and network meta-Analysis. Manchester, England: 15th International Congress of the Society for Melanoma Research. 2018. p. 76–77.

[48] Koruth RS RM, Kanters S, Druyts E. Dabrafenib and trametinib combination versus other interventions as adjuvant therapy for advanced cutaneous melanoma: a network meta-analysis. Manchester, England: Proceedings of the 15th International Congress of the Society for Melanoma Research. 2018. p. 35–36.

[49] Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp Oncol (Poln). 2018;22:68–72.